Cargando…
Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders
AIM: In a recent randomized, multicenter trial (NCT02814838) a short-term anti-inflammatory treatment with ladarixin (LDX; an inhibitor of the CXCR1/2 chemokine receptors) did not show benefit on preserving residual beta cell function in new-onset type 1 diabetes. We present a post hoc analysis of t...
Autores principales: | Sordi, Valeria, Monti, Paolo, Lampasona, Vito, Melzi, Raffaella, Pellegrini, Silvia, Keymeulen, Bart, Gillard, Pieter, Linn, Thomas, Bosi, Emanuele, Rose, Ludger, Pozzilli, Paolo, Giorgino, Francesco, Cossu, Efisio, Piemonti, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319139/ https://www.ncbi.nlm.nih.gov/pubmed/37409229 http://dx.doi.org/10.3389/fendo.2023.1175640 |
Ejemplares similares
-
Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial
por: Piemonti, Lorenzo, et al.
Publicado: (2022) -
miR-204 is associated with an endocrine phenotype in human pancreatic islets but does not regulate the insulin mRNA through MAFA
por: Marzinotto, Ilaria, et al.
Publicado: (2017) -
Alloantibody and Autoantibody Monitoring Predicts Islet Transplantation Outcome in Human Type 1 Diabetes
por: Piemonti, Lorenzo, et al.
Publicado: (2013) -
The potential and challenges of alternative sources of β cells for the cure of type 1 diabetes
por: Cito, Monia, et al.
Publicado: (2018) -
No Evidence of Long-Term Disruption of Glycometabolic Control After SARS-CoV-2 Infection
por: Laurenzi, Andrea, et al.
Publicado: (2021)